IL144461A0 - Quinoline and quinazoline derivatives and pharmaceutical compositions containing them - Google Patents

Quinoline and quinazoline derivatives and pharmaceutical compositions containing them

Info

Publication number: IL144461A0
Authority: IL; Israel
Prior art keywords: represent; pharmaceutical compositions; quinoline; alkyl; compositions containing
Prior art date: 1999-01-22

Application number

IL14446100A

Other languages

English (en)

Original Assignee

Kirin Brewery

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-22

Filing date

2000-01-20

Publication date

2002-05-23

2000-01-20 Application filed by Kirin Brewery filed Critical Kirin Brewery

2002-05-23 Publication of IL144461A0 publication Critical patent/IL144461A0/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
125000000217 alkyl group Chemical group 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
125000004414 alkyl thio group Chemical group 0.000 abstract 1
125000000304 alkynyl group Chemical group 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
125000003710 aryl alkyl group Chemical group 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
125000005415 substituted alkoxy group Chemical group 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Quinoline Compounds (AREA)
Pyrane Compounds (AREA)

IL14446100A 1999-01-22 2000-01-20 Quinoline and quinazoline derivatives and pharmaceutical compositions containing them IL144461A0 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
JP1485899		1999-01-22
JP2669199		1999-02-03
JP14249399		1999-05-21
JP25362499		1999-09-07
PCT/JP2000/000255 WO2000043366A1 (en)	1999-01-22	2000-01-20	Quinoline derivatives and quinazoline derivatives

Publications (1)

Publication Number	Publication Date
IL144461A0 true IL144461A0 (en)	2002-05-23

Family

ID=27456291

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL14446100A IL144461A0 (en)	1999-01-22	2000-01-20	Quinoline and quinazoline derivatives and pharmaceutical compositions containing them
IL144461A IL144461A (en)	1999-01-22	2001-07-19	History of quinoline and quinazoline and pharmaceutical preparations containing them

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL144461A IL144461A (en)	1999-01-22	2001-07-19	History of quinoline and quinazoline and pharmaceutical preparations containing them

Country Status (19)

Country	Link
US (3)	US6797823B1 (de)
EP (2)	EP1384712B1 (de)
JP (2)	JP3519368B2 (de)
KR (1)	KR100787254B1 (de)
CN (1)	CN1183114C (de)
AT (2)	ATE356117T1 (de)
AU (1)	AU771504B2 (de)
BR (1)	BR0007656A (de)
CA (1)	CA2361057C (de)
DE (2)	DE60033857T2 (de)
ES (2)	ES2208261T3 (de)
HU (1)	HU230789B1 (de)
IL (2)	IL144461A0 (de)
NO (1)	NO321295B1 (de)
NZ (1)	NZ513006A (de)
PL (2)	PL206627B1 (de)
TR (1)	TR200102090T2 (de)
TW (1)	TWI229667B (de)
WO (1)	WO2000043366A1 (de)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7329670B1 (en)	1997-12-22	2008-02-12	Bayer Pharmaceuticals Corporation	Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en)	1997-12-22	2009-04-14	Bayer Pharmaceuticals Corporation	Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP1140840B1 (de)	1999-01-13	2006-03-22	Bayer Pharmaceuticals Corp.	-g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
US7351834B1 (en)	1999-01-13	2008-04-01	Bayer Pharmaceuticals Corporation	ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (en)	1999-01-13	2013-10-08	Bayer Healthcare Llc	.omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
CA2361057C (en) *	1999-01-22	2010-04-06	Kazuo Kubo	Quinoline derivatives and quinazoline derivatives
US7135466B2 (en)	1999-12-24	2006-11-14	Kirin Beer Kabushiki Kaisha	Quinoline and quinazoline derivatives and drugs containing the same
EP1415987B1 (de) *	2000-10-20	2007-02-28	Eisai R&D Management Co., Ltd.	Stickstoff-enthaltende aromatische ringverbindungen zur behandlung von tumorerkrankungen
GB0029015D0 (en)	2000-11-28	2001-01-10	Univ London	Medical device
US7235576B1 (en)	2001-01-12	2007-06-26	Bayer Pharmaceuticals Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en)	2001-04-20	2008-05-13	Bayer Pharmaceuticals Corporation	Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
DE60208364T2 (de) *	2001-04-27	2006-09-28	Kirin Beer K.K.	Chinolinderivate mit einer azolylgruppe und chinazolinderivate
CA2454538A1 (en) *	2001-06-22	2003-01-03	Kirin Beer Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives capable of inhibiting autophosphorylation of hepatocyte growth factor receptors, and pharmaceutical composition comprising the same
WO2003008388A1 (en) *	2001-07-19	2003-01-30	Kirin Beer Kabushiki Kaisha	I-form crystal of n-{2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl}-n'-propylurea and process for producing the same
WO2003033472A1 (en) *	2001-10-17	2003-04-24	Kirin Beer Kabushiki Kaisha	Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
CN1625555A (zh)	2002-02-01	2005-06-08	阿斯特拉曾尼卡有限公司	喹唑啉化合物
US20030216396A1 (en)	2002-02-11	2003-11-20	Bayer Corporation	Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
SI1580188T1 (sl)	2002-02-11	2012-02-29	Bayer Healthcare Llc	Aril sečnine kot kinazni inhibitorji
EP2324825A1 (de)	2002-02-11	2011-05-25	Bayer Healthcare LLC	Arylharnstoffe mit Angiogenese hemmender Aktivität
US7598258B2 (en) *	2002-05-01	2009-10-06	Kirin Beer Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
US7202244B2 (en)	2002-05-29	2007-04-10	Millennium Pharmaceuticals, Inc.	Chk-1 inhibitors
ES2400339T3 (es)	2002-07-15	2013-04-09	Symphony Evolution, Inc.	Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
EP1566379A4 (de) *	2002-10-29	2005-11-09	Kirin Brewery	CHINOLINDERIVATE UND CHINAZOLINDERIVATE ALS HEMMER DER Flt3-AUTOPHOSPHORYLIERUNG UND DIESE ENTHALTENDE MEDIZINISCHE ZUSAMMENSETZUNGEN
UY28213A1 (es)	2003-02-28	2004-09-30	Bayer Pharmaceuticals Corp	Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1604665B1 (de)	2003-03-10	2011-05-11	Eisai R&D Management Co., Ltd.	C-kit kinase-hemmer
CA2518465A1 (en)	2003-03-25	2004-10-14	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
US7638638B2 (en)	2003-05-14	2009-12-29	Takeda San Diego, Inc.	Dipeptidyl peptidase inhibitors
DE602004007382T2 (de)	2003-05-20	2008-04-17	Bayer Pharmaceuticals Corp., West Haven	Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
DK1663978T3 (da)	2003-07-23	2008-04-07	Bayer Pharmaceuticals Corp	Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
KR20060041309A (ko)	2003-08-13	2006-05-11	다케다 야쿠힌 고교 가부시키가이샤	４-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
AU2013204031B2 (en) *	2003-09-26	2016-10-27	Exelixis, Inc.	c-Met modulators and methods of use
CA2744997A1 (en) *	2003-09-26	2005-04-07	Exelixis, Inc.	C-met modulators and method of use
WO2005044788A1 (ja)	2003-11-11	2005-05-19	Eisai Co., Ltd.	ウレア誘導体およびその製造方法
EP1690856A4 (de) *	2003-11-28	2007-09-05	Aveo Pharmaceuticals Inc	Chinazolinderivat und verfahren zu dessen herstellung
JP4503022B2 (ja)	2003-12-23	2010-07-14	ファイザー・インク	新規キノリン誘導体
TW200530236A (en)	2004-02-23	2005-09-16	Chugai Pharmaceutical Co Ltd	Heteroaryl phenylurea
US7459562B2 (en)	2004-04-23	2008-12-02	Bristol-Myers Squibb Company	Monocyclic heterocycles as kinase inhibitors
TW200538453A (en)	2004-04-26	2005-12-01	Bristol Myers Squibb Co	Bicyclic heterocycles as kinase inhibitors
JP2007535565A (ja)	2004-04-30	2007-12-06	バイエルファーマシューティカルスコーポレーション	癌の治療に有用な置換ピラゾリル尿素誘導体
US7432373B2 (en)	2004-06-28	2008-10-07	Bristol-Meyers Squibb Company	Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US20050288290A1 (en)	2004-06-28	2005-12-29	Borzilleri Robert M	Fused heterocyclic kinase inhibitors
US7439246B2 (en)	2004-06-28	2008-10-21	Bristol-Myers Squibb Company	Fused heterocyclic kinase inhibitors
US8426429B2 (en)	2004-08-06	2013-04-23	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8383637B2 (en) *	2004-08-06	2013-02-26	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
US8436006B2 (en) *	2004-08-06	2013-05-07	Jansssen Pharmaceutica N.V.	2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE)
ATE428421T1 (de)	2004-09-17	2009-05-15	Eisai R&D Man Co Ltd	Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
US7652009B2 (en) *	2004-11-30	2010-01-26	Amgem Inc.	Substituted heterocycles and methods of use
KR101335932B1 (ko) *	2005-03-07	2013-12-04	바이엘 헬스케어 엘엘씨	암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물
JO2787B1 (en) *	2005-04-27	2014-03-15	امجين إنك,	Alternative amide derivatives and methods of use
TW200740820A (en) *	2005-07-05	2007-11-01	Takeda Pharmaceuticals Co	Fused heterocyclic derivatives and use thereof
WO2007015569A1 (ja) *	2005-08-01	2007-02-08	Eisai R & D Management Co., Ltd.	血管新生阻害物質の効果を予測する方法
EP1925676A4 (de)	2005-08-02	2010-11-10	Eisai R&D Man Co Ltd	Testverfahren für die wirkung eines vaskularisierungsinhibitors
EP1938842A4 (de) *	2005-09-01	2013-01-09	Eisai R&D Man Co Ltd	Verfahren zur herstellung einer pharmazeutischen zusammensetzung mit verbesserten zerfallseigenschaften
AU2006290205B2 (en)	2005-09-14	2012-12-13	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors for treating diabetes
CA2622642C (en)	2005-09-16	2013-12-31	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
CN101316590B (zh)	2005-11-07	2011-08-03	卫材R&D管理有限公司	血管生成抑制剂和c-kit激酶抑制剂的组合使用
WO2007061127A1 (ja) *	2005-11-22	2007-05-31	Eisai R & D Management Co., Ltd.	多発性骨髄腫に対する抗腫瘍剤
US7868022B2 (en) *	2006-02-06	2011-01-11	Janssen Pharmaceutica Nv	2-amino-quinoline derivatives useful as inhibitors of β-secretase (BACE)
WO2007092839A2 (en) *	2006-02-06	2007-08-16	Janssen Pharmaceutica N.V.	Macrocycle derivatives useful as inhibitors of beta-secretase (bace)
WO2007092846A2 (en) *	2006-02-06	2007-08-16	Janssen Pharmaceutica N.V.	2-AMINO-3,4-DIHYDRO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE)
WO2007112347A1 (en)	2006-03-28	2007-10-04	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
WO2007136103A1 (ja) *	2006-05-18	2007-11-29	Eisai R & D Management Co., Ltd.	甲状腺癌に対する抗腫瘍剤
EP2044939A1 (de) *	2006-06-29	2009-04-08	Eisai R&D Management Co., Ltd.	Therapeutisches mittel gegen leberfibrose
BRPI0714665A2 (pt)	2006-08-04	2012-03-13	Takeda Pharmaceutical Company Limited	Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer
WO2008020302A2 (en) *	2006-08-17	2008-02-21	Pfizer Products Inc.	Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
KR101472600B1 (ko) *	2006-08-28	2014-12-15	에자이 알앤드디 매니지먼트 가부시키가이샤	미분화형 위암에 대한 항종양제
WO2008044688A1 (en) *	2006-10-11	2008-04-17	Daiichi Sankyo Company, Limited	Urea derivative
TW200838536A (en)	2006-11-29	2008-10-01	Takeda Pharmaceutical	Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
JPWO2008087736A1 (ja) *	2007-01-19	2010-05-06	宇部興産株式会社	アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
EP2119707B1 (de)	2007-01-29	2015-01-14	Eisai R&D Management Co., Ltd.	Zusammensetzung zur behandlung von nicht differenzierten formen von magenkrebsen
US8557853B2 (en) *	2007-02-09	2013-10-15	Allergan, Inc.	Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents
CL2008001626A1 (es)	2007-06-05	2009-06-05	Takeda Pharmaceuticals Co	Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
JP5270553B2 (ja) *	2007-08-23	2013-08-21	武田薬品工業株式会社	複素環化合物およびその用途
CN101848895B (zh)	2007-11-09	2013-10-23	卫材R&D管理有限公司	血管新生抑制物质和抗肿瘤性铂络合物的组合使用
AU2008337286B2 (en) *	2007-12-19	2014-08-07	Cancer Research Technology Limited	Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
US7863283B2 (en) *	2008-01-17	2011-01-04	Bayer Schering Pharma Ag	Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments
NZ586831A (en) *	2008-01-28	2012-02-24	Janssen Pharmaceutica Nv	6-substituted-thio-2-amino-quinoline derivatives useful as inhibitors of beta-secretase (bace)
EP2240472B1 (de) *	2008-01-29	2012-11-21	Janssen Pharmaceutica NV	Als inhibitoren von beta-sekretase (bace) geeignete 2-aminochinolinderivate
US20100324087A1 (en) *	2008-01-29	2010-12-23	Eisai R&D Management Co., Ltd.	Combined use of angiogenesis inhibitor and taxane
PL2947072T3 (pl) *	2008-03-17	2017-05-31	Ambit Biosciences Corporation	1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
JP5746015B2 (ja) *	2008-04-16	2015-07-08	マックスプランクゲゼルシャフトツゥアーフェデルゥンデルヴィッセンシャフテンエーフォー	Ａｘｌキナーゼ阻害剤としてのキノリン誘導体
CA2740746A1 (en) *	2008-10-14	2010-04-22	Ning Xi	Compounds comprising a spiro-ring and and methods of use
US8697874B2 (en) *	2008-12-01	2014-04-15	Takeda Pharmaceutical Company Limited	Heterocyclic compound and use thereof
JO3101B1 (ar)	2008-12-02	2017-09-20	Takeda Pharmaceuticals Co	مشتقات بنزوثيازول كعوامل مضادة للسرطان
EA038195B1 (ru)	2009-01-16	2021-07-22	Экселиксис, Инк.	Малатная соль n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида и ее применение для лечения рака почек и печени
EP2408300B1 (de) *	2009-03-21	2016-05-11	Sunshine Lake Pharma Co., Ltd.	Aminoesterderivate, salze daraus und verfahren zu ihrer verwendung
WO2010108503A1 (en)	2009-03-24	2010-09-30	Life & Brain Gmbh	Promotion of neuronal integration in neural stem cell grafts
CN101671301B (zh) *	2009-05-05	2014-02-26	江苏省药物研究所有限公司	杂环取代的二苯脲类衍生物及其用途
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
BR112012003592B8 (pt)	2009-08-19	2021-05-25	Eisai R&D Man Co Ltd	composição farmacêutica contendo derivado de quinolina
CA2802644C (en)	2010-06-25	2017-02-21	Eisai R & D Management Co., Ltd.	Antitumor agent using compounds having kinase inhibitory effect in combination
US20130225581A1 (en)	2010-07-16	2013-08-29	Kyowa Hakko Kirin Co., Ltd	Nitrogen-containing aromatic heterocyclic derivative
TWI640509B (zh) *	2011-02-10	2018-11-11	艾克塞里克斯公司	製造喹啉化合物之方法及包含該化合物之醫藥組合物
EP2700403B1 (de)	2011-04-18	2015-11-25	Eisai R&D Management Co., Ltd.	Therapeutikum für tumor
WO2012166899A2 (en)	2011-06-03	2012-12-06	Eisai R&D Management Co., Ltd.	Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102311395B (zh) *	2011-07-05	2014-04-16	张爱华	喹唑啉环取代的二苯脲类衍生物及其用途
CN102432595B (zh) *	2011-09-14	2013-09-25	湖南有色凯铂生物药业有限公司	N-吲哚-1-酰胺类化合物及作为抗癌药物的应用
CN102408418A (zh) *	2011-10-21	2012-04-11	武汉迈德森医药科技有限公司	Tivozanib酸性盐及其制备方法和晶型
UY34451A (es)	2011-11-14	2013-05-31	Cephalon Inc	Derivados de uracilo como inhibidores de la quinasa axl y c-met
CN102603718B (zh) *	2012-02-08	2014-01-29	武汉凯斯瑞科技有限公司	西地尼布的合成方法
EP2626073A1 (de)	2012-02-13	2013-08-14	Harmonic Pharma	Verbindung zur Verwendung zur Prävention bzw. Behandlung einer neurogenerativen Erkrankung oder einer Erkrankung mit Phosphodiesterase (PDE4) -4-Aktivierung
AU2013364953A1 (en)	2012-12-21	2015-04-30	Eisai R&D Management Co., Ltd.	Amorphous form of quinoline derivative, and method for producing same
WO2014127335A1 (en) *	2013-02-15	2014-08-21	Kala Pharmaceuticals, Inc.	Therapeutic compounds and uses thereof
CA2900652C (en) *	2013-02-15	2021-05-04	Kala Pharmaceuticals, Inc.	Therapeutic compounds and uses thereof
CN105264380B (zh)	2013-05-14	2017-09-05	卫材R&D管理有限公司	用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
CA2957005C (en)	2014-08-28	2021-10-12	Eisai R&D Management Co., Ltd.	High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en)	2015-02-25	2017-09-28	Eisai R&D Man Co Ltd	Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en)	2015-03-04	2016-09-09	Merck Sharp & Dohme Corp.	Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (pt)	2015-06-16	2023-12-12	Eisai R&D Management Co., Ltd	Agente anti-câncer
JP6553726B2 (ja)	2015-08-20	2019-07-31	エーザイ・アール・アンド・ディー・マネジメント株式会社	腫瘍治療剤
US20190112317A1 (en)	2015-10-05	2019-04-18	The Trustees Of Columbia University In The City Of New York	Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN106496116A (zh) *	2016-10-21	2017-03-15	沈阳药科大学	含双芳基脲结构的喹啉类化合物及其用途
JP7105774B2 (ja)	2016-12-01	2022-07-25	イグナイタインコーポレイテッド	がん治療のための方法
CN108239067A (zh) *	2016-12-27	2018-07-03	沈阳药科大学	喹唑啉酮类衍生物及其制备方法和用途
US12303505B2 (en)	2017-02-08	2025-05-20	Eisai R&D Management Co., Ltd.	Tumor-treating pharmaceutical composition
BR112019023064A2 (pt)	2017-05-16	2020-06-09	Eisai R&D Man Co Ltd	tratamento de carcinoma hepatocelular
CN109824587A (zh) *	2017-11-23	2019-05-31	上海翔锦生物科技有限公司	酪氨酸激酶抑制剂xjf007及其中间体的制备方法
CN109553581B (zh) *	2018-09-25	2022-01-25	广州六顺生物科技股份有限公司	取代脲化合物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物
CN111303024B (zh) *	2018-12-12	2023-03-28	安徽中科拓苒药物科学研究有限公司	一种喹啉结构的pan-KIT激酶抑制剂及其用途
JP2020100598A (ja)	2018-12-25	2020-07-02	公益財団法人応用生化学研究所	レンバチニブ誘導体、並びにそれを用いた医薬研究用組成物及び腫瘍治療剤
WO2021144360A1 (en)	2020-01-17	2021-07-22	F. Hoffmann-La Roche Ag	Small molecule csf-1r inhibitors in therapeutic and cosmetic uses
CN113620873B (zh) *	2020-05-07	2023-12-08	沈阳药科大学	含锌结合基以及喹啉骨架的化合物的制备方法和用途
CN116763787A (zh) *	2022-03-08	2023-09-19	安徽中科拓苒药物科学研究有限公司	喹啉类化合物的新用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5480883A (en)	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JP2783722B2 (ja) *	1991-07-12	1998-08-06	麒麟麦酒株式会社	スピカマイシン誘導体およびそれを含む抗腫瘍剤
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
FI971138L (fi) *	1994-09-20	1997-03-18	Sumitomo Metal Ind	Keraamisia eristeitä ja menetelmiä niiden muodostamiseksi
WO1997017329A1 (en) *	1995-11-07	1997-05-15	Kirin Beer Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
JP4194678B2 (ja) *	1997-11-28	2008-12-10	キリンファーマ株式会社	キノリン誘導体およびそれを含む医薬組成物
CA2361057C (en) *	1999-01-22	2010-04-06	Kazuo Kubo	Quinoline derivatives and quinazoline derivatives
US7135466B2 (en) *	1999-12-24	2006-11-14	Kirin Beer Kabushiki Kaisha	Quinoline and quinazoline derivatives and drugs containing the same
DE60208364T2 (de) *	2001-04-27	2006-09-28	Kirin Beer K.K.	Chinolinderivate mit einer azolylgruppe und chinazolinderivate
WO2003033472A1 (en) *	2001-10-17	2003-04-24	Kirin Beer Kabushiki Kaisha	Quinoline or quinazoline derivatives inhibiting auto- phosphorylation of fibroblast growth factor receptors
US7598258B2 (en) *	2002-05-01	2009-10-06	Kirin Beer Kabushiki Kaisha	Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
JP3763414B2 (ja) *	2002-10-21	2006-04-05	麒麟麦酒株式会社	Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形
EP1566379A4 (de) *	2002-10-29	2005-11-09	Kirin Brewery	CHINOLINDERIVATE UND CHINAZOLINDERIVATE ALS HEMMER DER Flt3-AUTOPHOSPHORYLIERUNG UND DIESE ENTHALTENDE MEDIZINISCHE ZUSAMMENSETZUNGEN
US20040229676A1 (en) *	2003-04-28	2004-11-18	Gerald Duhamel	Method of playing a game of chance

2000
- 2000-01-20 CA CA2361057A patent/CA2361057C/en not_active Expired - Fee Related
- 2000-01-20 AT AT03024911T patent/ATE356117T1/de not_active IP Right Cessation
- 2000-01-20 HU HU0105133A patent/HU230789B1/hu unknown
- 2000-01-20 DE DE60033857T patent/DE60033857T2/de not_active Expired - Lifetime
- 2000-01-20 DE DE60006216T patent/DE60006216T2/de not_active Expired - Lifetime
- 2000-01-20 EP EP03024911A patent/EP1384712B1/de not_active Expired - Lifetime
- 2000-01-20 IL IL14446100A patent/IL144461A0/xx active IP Right Grant
- 2000-01-20 AT AT00900841T patent/ATE253051T1/de not_active IP Right Cessation
- 2000-01-20 EP EP00900841A patent/EP1153920B1/de not_active Expired - Lifetime
- 2000-01-20 ES ES00900841T patent/ES2208261T3/es not_active Expired - Lifetime
- 2000-01-20 JP JP2000594782A patent/JP3519368B2/ja not_active Expired - Fee Related
- 2000-01-20 WO PCT/JP2000/000255 patent/WO2000043366A1/ja not_active Ceased
- 2000-01-20 PL PL388667A patent/PL206627B1/pl not_active IP Right Cessation
- 2000-01-20 BR BR0007656-2A patent/BR0007656A/pt active Search and Examination
- 2000-01-20 KR KR1020017009144A patent/KR100787254B1/ko not_active Expired - Fee Related
- 2000-01-20 AU AU30748/00A patent/AU771504B2/en not_active Ceased
- 2000-01-20 CN CNB008054282A patent/CN1183114C/zh not_active Expired - Fee Related
- 2000-01-20 US US09/889,858 patent/US6797823B1/en not_active Expired - Fee Related
- 2000-01-20 NZ NZ513006A patent/NZ513006A/en not_active IP Right Cessation
- 2000-01-20 PL PL349036A patent/PL204856B1/pl not_active IP Right Cessation
- 2000-01-20 ES ES03024911T patent/ES2281591T3/es not_active Expired - Lifetime
- 2000-01-20 TR TR2001/02090T patent/TR200102090T2/xx unknown
- 2000-01-21 TW TW089100998A patent/TWI229667B/zh not_active IP Right Cessation
2001
- 2001-05-29 NO NO20012617A patent/NO321295B1/no not_active IP Right Cessation
- 2001-07-19 IL IL144461A patent/IL144461A/en not_active IP Right Cessation
2003
- 2003-05-06 JP JP2003128216A patent/JP2003286263A/ja not_active Withdrawn
2004
- 2004-05-10 US US10/842,009 patent/US7169789B2/en not_active Expired - Fee Related
2006
- 2006-09-26 US US11/526,739 patent/US20070027318A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60033857D1 (de)	2007-04-19
EP1153920B1 (de)	2003-10-29
HK1043792A1 (en)	2002-09-27
DE60033857T2 (de)	2007-10-25
ES2208261T3 (es)	2004-06-16
DE60006216T2 (de)	2004-07-15
HU230789B1 (en)	2018-05-02
CN1183114C (zh)	2005-01-05
WO2000043366A1 (en)	2000-07-27
AU771504B2 (en)	2004-03-25
PL206627B1 (pl)	2010-09-30
CA2361057C (en)	2010-04-06
EP1153920A4 (de)	2002-04-17
AU3074800A (en)	2000-08-07
PL204856B1 (pl)	2010-02-26
CA2361057A1 (en)	2000-07-27
BR0007656A (pt)	2001-10-30
ES2281591T3 (es)	2007-10-01
NZ513006A (en)	2003-10-31
KR100787254B1 (ko)	2007-12-20
JP3519368B2 (ja)	2004-04-12
KR20010101857A (ko)	2001-11-15
JP2003286263A (ja)	2003-10-10
DE60006216D1 (de)	2003-12-04
US20040209905A1 (en)	2004-10-21
NO321295B1 (no)	2006-04-18
NO20012617D0 (no)	2001-05-29
NO20012617L (no)	2001-09-14
HUP0105133A2 (hu)	2002-07-29
CN1344254A (zh)	2002-04-10
EP1153920A1 (de)	2001-11-14
TR200102090T2 (tr)	2002-01-21
IL144461A (en)	2007-07-04
US20070027318A1 (en)	2007-02-01
PL349036A1 (en)	2002-07-01
HUP0105133A3 (en)	2002-09-30
EP1384712A1 (de)	2004-01-28
US7169789B2 (en)	2007-01-30
TWI229667B (en)	2005-03-21
EP1384712B1 (de)	2007-03-07
US6797823B1 (en)	2004-09-28
ATE356117T1 (de)	2007-03-15
ATE253051T1 (de)	2003-11-15

Legal Events

Date	Code	Title
2007-12-03	FF	Patent granted
2008-01-22	KB	Patent renewed
2010-06-16	KB	Patent renewed

Publication	Publication Date	Title
PL349036A1 (en)	2002-07-01	Quinoline derivatives and quinazoline derivatives
IL158459A0 (en)	2004-05-12	Quinoline derivatives and quinazoline derivatives having azolyl group
DE69418704D1 (de)	1999-07-01	Anthranilsäure derivate
DK0622361T3 (da)	2001-12-03	Heterocykliske forbindelser som bradykininantagonister
IL111959A0 (en)	1995-06-29	Benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
MX9700883A (es)	1997-08-30	Derivados sustituidos de la quinazolina.
PT976748E (pt)	2004-03-31	Derivados de pirrolidina com actividade inibidora de fosfolipase a2
AU2492500A (en)	2000-07-24	Aspartic protease inhibitors, compositions, and associated therapeutic methods
DK1847534T3 (da)	2011-08-29	Thiadiazolin-derivater til behandling af kræft
DE60016384D1 (de)	2005-01-05	Chondrogonese promotoren und indolin-2-on derivate
IL157216A0 (en)	2004-02-19	Crystalline forms of pyrimidine nucleoside derivatives and pharmaceutical compositions containing the same
MXPA04001171A (es)	2004-05-20	Compuestos policiclicos condensados.
AU3387301A (en)	2001-08-27	Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
EP1466900A4 (de)	2005-07-20	2-substituierte vitamin-d-derivate
EP1251129A4 (de)	2003-03-05	Pyrimidinderivate mit antitumor-wirkung